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Abstract— Enzymatic acetylations of N-substituted cis- and trans-3,4-dihydroxypiperidine and hydrolysis of their diacetylated derivatives 
have been studied. High enantioselectivities are obtained with Pseudomonas cepacia lipase and Candida antarctica lipase B for the 
hydrolysis of the trans-derivative, while the cis-derivatives are not adequate substrates in the same biocatalytic conditions. The 
enantiopreference of these processes can be rationalized by means of a molecular modelling study. 
——— 
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1. Introduction 
Polyhydroxylated piperidines have attracted great interest 
due to their biological properties. Some of them are 
inhibitors of glycosidases and glycoprotein-processing 
enzymes.
1
 These inhibitors have shown a promising 
therapeutical potential for the treatment of various diseases 
related to metabolic disorders of carbohydrates such as 
diabetes,
2
 and viral infections including AIDS
3
 or cancer.
4
 
In this sense, optically pure 3,4-dihydroxypiperidine is an 
interesting structure since the (3R,4R)-trans isomer is an 
inhibitor of -D-glucoronidase5 and has been used as 
intermediate for the preparation of a xylanase inhibitor 
(Figure 1).
6
 Also, this structure is a suitable precursor of the 
gastroprokinetic agent cisapride.
7
 On the other hand, the 
cis-isomer is an intermediate for the preparation of the 
antidepressant ifoxetine.
8
  
The optically pure (3R,4R)-trans-isomer has been 
synthesized from either D-arabinose
5
 or D-tartaric acid.
6
 
Both routes require a large number of steps to afford the 
desired compound in low overall yields. Recently, Chang et 
al.
9
 have reported the preparation of the optically pure 
trans-isomers using enantioselective trans-
dihydroxylations or epoxidations of N-substituted 1,2,5,6-
tetrahydropyridines, catalyzed by the bacterial strain 
Sphingomonas sp. HXN-200. 
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Figure 1. Examples of different chiral 3,4-dihydroxypiperidine 
derivatives. 
On the other hand, lipase-catalyzed processes in organic 
solvents are very advantageous alternatives to the 
conventional chemical reactions, that have been widely 
used for the preparation of optically pure cycloalkanediols
10
 
and carbosugars.
11 
Nevertheless, to the best of our 
knowledge, the use of this methodology for the preparation 
of polyhydroxylated piperidines has not been studied until 
now. This paper describes the acetylation of N-protected 
cis- and trans-3,4-dihydroxypiperidine and the hydrolysis 
of their diacetylated derivatives catalyzed by lipases. Some 
of the results presented here have been rationalized using a 
computational approach. 
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2. Results and discussion 
Our initial experiments were designed to find the most 
suitable lipase for catalyzing the hydrolysis of the 
diacetylated derivative (±)-trans-4. This substrate has been 
prepared almost in quantitative yield by treatment of 1-
benzyloxycarbonyl-1,2,5,6-tetrahydropyridine (2) with m-
chloroperbenzoic acid (m-CPBA) in CH2Cl2 and 
subsequent opening of the resulting epoxide (±)-3 with 
acetic anhydride and BF3
.
Et2O (Scheme 1). 
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Scheme 1. Synthesis of (±)-trans-4. 
First, we studied the hydrolysis of (±)-trans-4, in aqueous 
media (phosphate buffer, pH 7). In these conditions, the 
non-enzymatic hydrolysis occurred in competition with the 
enzymatic reaction. So, we decided to examine the process 
in organic solvents using a small amount of water as 
nucleophile (Scheme 2). 
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Scheme 2. Enzymatic hydrolysis of (±)-trans-4 in organic solvents. 
Since we had previously obtained good results in these 
hydrolytic conditions,
12
 in a first set of experiments at 30 
ºC, acetonitrile was chosen as the reaction solvent and 
different lipases were used as biocatalysts: Candida 
antarctica A (CAL-A), Candida antarctica B in two forms 
[Novozym 435 (CAL-B) and Chirazyme-L2 (CAL-B-L2)], 
Candida rugosa (CRL) and Pseudomonas cepacia (PSL-
C). Three of the tested enzymes catalyzed the 
regioselective hydrolysis of (±)-trans-4 affording only the 
3-acetyl-4-hydroxy derivative (3R,4R)-5 (Table I, entries 1 
to 3). In all cases, the enzymatic reactions were 
regioselective towards the acetyl group at O-4 position. 
This was confirmed by means of a two dimensional 
1
H-
1
H-
COSY NMR analysis. 
The enantioselectivity of the enzymatic hydrolysis was also 
very high. Both immobilized forms of lipase B from 
Candida antarctica, CAL-B and CAL-B-L-2, showed the 
highest enantioselectivities (E > 200),
13
 with excellent 
reaction rates, after 24 h a 49 % conversion was achieved. 
The lipase PSL-C showed also a high enantioselectivity 
under these conditions, (E = 98), but displayed a lower 
reaction rate. In these conditions, CAL-A and CRL did not 
show any activity. 
The absolute configurations of the product and the 
remaining substrate were assigned as follows. Hydrolysis 
of (–)-trans-5 using NaOMe in MeOH, afforded the 
dihydroxy derivative (+)-trans-6, whose specific rotation 
sign was in agreement with that reported for (3R,4R)-(+)-6, 
[]20D = + 3.51 (c 0.76, CHCl3).
9
 
In order to improve the performance of the process, we 
studied the influence of the organic solvent on the 
enantioselectivity of the hydrolysis catalyzed by CAL-B. 
Thus, under the same reaction conditions, similar results 
were obtained in 1,4-dioxane than in acetonitrile (Table I, 
entry 4), even though it is apparent that in acetonitrile were 
slightly higher. Lower reaction rate and enantioselectivity 
were achieved in toluene (Table I, entry 5). Finally, an 
increase of the nucleophile concentration up to 10 
equivalents furnished lower conversion (Table I, entry 6). 
 
Table 1. Lipase catalyzed hydrolysis of (±)-trans-4 in organic solvents at 30ºC. 
a Conversion, c = ees/(ees + eep). 
b Determined by chiral HPLC. 
c Enantiomeric ratio, E = ln[(1 – c)((1 – ees)]/ln [(1 – c)((1 + ees)].
13 
 
Another common approach for the resolution of racemic 
polyalcohols is the enzymatic transesterification reaction.
14
 
So, we decided to synthesize the dihydroxypiperidine (±)-
trans-6, starting from the diacetate (±)-trans-4 and using 
Entry Lipase Solvent H2O (eq) t [h] c [%]
a ees [%]
b eep [%]
b Ec 
1 CAL-B Acetonitrile 5 24 49 97 >99 >200 
2 CAL-B-L2 Acetonitrile 5 24 49 96 >99 >200 
3 PSL-C Acetonitrile 5 24 8 9 98 98 
4 CAL-B 1,4-Dioxane 5 48 47 89 >99 >200 
5 CAL-B Toluene 5 24 10 9 83 12 
6 CAL-B Acetonitrile 10 24 36 54 >99 >200 
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NaOMe in MeOH. Taking into account that the best 
enzymes for the hydrolysis are both CAL-B preparations 
and PSL-C, we examined the acetylation of the dihydroxy 
derivative (±)-trans-6 catalyzed by these lipases (Scheme 3, 
Table II).  
First we carried out the process using 5 equivalents of vinyl 
acetate as acyl donor and acetonitrile as solvent. In these 
conditions, CAL-B-L2 and PSL-C catalyzed the processes 
with good reaction rates (entries 1 and 2), however both 
showed very low enantioselectivities. Surprisingly, in the 
process catalyzed by CAL-B, after 72 h of reaction only the 
unaltered substrate was recovered (entry 3). A fifty-fold 
excess of the acylating agent was necessary to obtain a 
moderate reaction rate with this catalyst (entry 4). Also a 
slightly improvement in the enantioselectivity was 
observed. 
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Scheme 3. Enzymatic acetylation of (±)-trans-6. 
As expected according to the principle of microscopic 
reversibility, the regio- and stereochemical preferences of 
these lipases were the same as for the hydrolytic processes: 
the hydroxyl group at C-4 position of the piperidine ring 
was preferentially acetylated to afford the product (3R,4R)-
7. In all cases, the formation of only one of the two possible 
regioisomers was observed. Unfortunately, the 
enantioselectivities of the enzymatic acylations were very 
low. Attempts to improve the results obtained in the 
reaction catalyzed by PSL-C, using different solvents such 
as toluene (entry 5) or tert-butyl methyl ether (entry 6) 
afforded also poor enantioselectivities, although these 
processes were faster.  
In order to establish the scope of this enantiomer separation 
methodology, similar biocatalytic conditions were applied 
for the hydrolysis of (±)-cis-N-benzyloxycarbonyl-3,4-
diacetoxypiperidine derivative. The substrate was 
synthesized according to the Scheme 4. Treatment of 1-
benzyloxycarbonyl-1,2,5,6-tetrahydropyridine (2) with 
OsO4 and N-methylmorpholine N-oxide (NMMO) yielded 
the diol (±)-cis-8, that was acetylated to the corresponding 
diacetate derivative (±)-cis-9.  
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Scheme 4. Synthesis of (±)-cis-8 and (±)-cis-9. 
Unfortunately, the enzymatic hydrolysis carried out with 
this substrate showed, in all cases, very low reaction rates. 
For instance, the conversion of the reaction catalyzed by 
CAL-B in acetonitrile at 30 ºC, using 5 equivalents of water 
was less than 5% after 7 days of reaction. An increment of 
the temperature at 60 ºC or an excess of the nucleophile up 
to fifty-fold did not increase the reaction rate. Other lipases 
and different organic solvents were tested but no 
improvement on the reaction rate was obtained. Even more, 
when we analyzed the products using gas chromatography, 
we observed a mixture 1:1 of the two possible 
regioisomers. 
Similar results were achieved in the acetylation of the 
dihydroxyderivative (±)-cis-8. Very low reactivities and 
regioselectivities were found in all the tested conditions 
(data not shown). 
 
 
Table 2. Lipase catalyzed acetylation of (±)-trans-6 with vinyl acetate (VA) in organic solvents at 30 ºC. 
a Conversion, c = ees/(ees + eep). 
b Determined by chiral HPLC. 
c Enantiomeric ratio, E = ln[(1 – c)((1 – ees)]/ln [(1 – c)((1 + ees)].
13 
 
Entry Lipase Solvent VA (eq) t [h] c [%]a ees [%]
b eep [%]
b 
Ec 
1 CAL-B-L2 Acetonitrile 5 15 59 20 14 2 
2 PSL-C Acetonitrile 5 16 30 74 61 2 
3 CAL-B Acetonitrile 5 72 – – – – 
4 CAL-B Acetonitrile 50 22 30 19 13 9 
5 PSL-C Toluene 5 15 62 39 24 2 
6 PSL-C tBuOMe 5 15 68 25 11 2 
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Since all these lipase-catalyzed reactions were 
dramatically influenced by the stereochemistry of the 
chiral centres, we found of a great deal of interest to 
rationalize the experimental facts observed in the 
hydrolysis of the trans-derivative (±)-4 using a 
computational approach. Since the X-ray crystal structure 
of CAL-B was resolved,
15
 several molecular modelling
16
 
and molecular dynamics studies
17
 have been made in 
order to explain its excellent reactivity and selectivity 
with chiral alcohols and amines. These reports have been 
very useful to make rational design of this biocatalyst
18
 
with improved selectivities,
17b,19
 or catalyzing through 
novel reaction pathways.
20
 Thus, engineered CAL-B has 
been utilized to perform aldol,
21
 Michael-type additions,
22
 
or Baeyer-Villiger reactions.
23 
The restricted volume of the active site of this lipase has 
been used to rationalize its special properties. So, viewed 
with the catalytic triad Asp187-His224-Ser105 oriented 
from left to right, CAL-B presents two well-differed 
subsites: a) the large hydrophobic pocket (or acyl pocket) 
above the catalytic triad, which is lined by Leu140 and 
Leu144 at the top, Ile189 and Val190 on the left, as well 
as Val154 on the far right of the pocket. Deep in this 
subsite, Asp134 is on the left and Gln157 on the right; and 
b) the medium-sized pocket (so called nucleophile or 
stereospecificity pocket) below it, which is crowded by 
Trp104 at the bottom and the Leu278-Ala287 helix to the 
right. The acyl chains lie in the large subsite, while 
nucleophiles bind to the medium-sized pocket. This 
smaller subsite has been found as the key factor to the 
enantioselectivity of secondary alcohols.
24 
Thus, the fast-reacting enantiomer (following Kazlauskas’ 
rule,
25
 usually the R), places the medium-sized substituent 
into this subsite and the big one into the acyl pocket, 
while the slow enantiomer has to introduce them in the 
opposite orientation, existing more unfavourable steric 
interactions. This general rule for acyclic alcohols, is not 
so clear for cyclic one, due to although R-acylated or 
hydrolyzed enantiomers are usually obtained, in several 
cases has been observed that for 1,2-cis-cyclohexanols, 
lipase-catalyzed processes are not achieved or are not 
selective, in spite of the excellent enantioselectivity for 
their trans counterparts.
26
 There are no many examples of 
the use of molecular modelling to study CAL-B-catalyzed 
acylations or hydrolyses of cyclic alcohols.
16c,16d,16g
 Here 
we will use this tool to explain qualitatively the 
experimental results obtained for the hydrolysis at the 4-
position in the cyclic diacetate (±)-4. 
We have modelled the first tetrahedral intermediate (TI-1) 
since in the hydrolysis processes this is the structure 
where the ester is bound to the lipase, and is the 
responsible of the enantioselection. Phosphonate 
analogues were used for mimicking this intermediate 
using the AMBER force field,
27
 and several local energy 
minima were obtained for each enantiomer by means of a 
systematically search, as described elsewhere.
16g
 The 
selection of the best structures was based in two main 
criteria: a) those that presented the most possible of the 
six essential hydrogen-bonds [one between Asp187 and 
Nδ-His224; one between Nε-His224 and Oγ-Ser105; one 
between Nε-His224 and the proton-acceptor oxygen of the 
acetate; and three between the oxygen of the oxyanion 
formed with Gln106 (one) and Thr40 (two)]; and b) those 
that minimized the steric clashes between the phosphonate 
and the amino acids which surrounded the active site of 
CAL-B. In general, the nucleophile pocket restricted the 
binding of the substrate to such an extent that only a few 
conformations were obtained with the desired properties. 
We started with the minimization of the intermediate for 
the hydrolysis in the 4-position of (3R,4R)-4. This 
enantiomer was experimentally the fast-reacting one. We 
used the X-ray structure 1LBS
16a
 obtained from the 
Protein Data Bank (http://www.rcsb.org/pdb/), which 
presented an inhibitor phosphonate that was manually 
deleted, and then the substrate was built.
16g 
When the bulky benzyloxycarbonyl moiety was manually 
added to the phosphonate and minimized, two families of 
intermediates were usually got. In both cases this group 
was accommodated into the narrow tunnel created by 
Ile189, Leu278, Ala281, Ala282, Ile285, and Val286, but 
with different orientations. Some of them (usually more 
stable), presented this moiety on the left, with the phenyl 
group close to Ile189 and Leu278, and the other one had 
the phenyl ring on the right side near from Ala282, 
Ile285, and Val286 pointing to the solvent. 
 
Figure 2. Best intermediate obtained for the CAL-B-catalyzed acylation 
of (3R,4R)-4. Amino acids which make stabilizing interactions with the 
3-O-acetyl group of the substrate are depicted in green, and those with 
the N-benzyloxycarbonyl moiety are shown in dark blue. The above 
image displays Leu144 in a line illustration and Ile189 in a stick 
representation to allow a better view of the large pocket of the lipase. 
The best structure obtained for (3R,4R)-4 is shown in 
Figure 2. As described previously,
16b,16g
 the cycle was 
placed into the stereospecificity pocket, with the acetyl 
group in the 3-position fitted into the acyl pocket, 
generating appropriate interactions between the methyl 
group with Val154 and the carbonyl moiety with the 
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hydrophilic side chains of Gln157 and Thr40. The 
benzyloxycarbonyl group was on the left of the tunnel 
with the phenyl ring making stabilizing hydrophobic 
interactions with the side chains of Ile189, Glu188, and 
Leu278, with the carbonyl group making a H-bond with 
the NH-backbone of the Ala282 (3.03 Å), and the 
methylene moiety interacting with the hydrophobic side 
chain of Ala282. All key-hydrogen bonds were present in 
this structure. 
 
Figure 3. Best intermediate obtained for the CAL-B-catalyzed acylation 
of (3S,4S)-4. Amino acids which make destabilizing interactions with 
the 3-O-acetyl group of the substrate are depicted in red and with the N-
benzyloxycarbonyl moiety are shown in violet. The above image 
displays Ile189 in a line illustration and Glu188 and Leu278 in a stick 
representation to allow a better view of the phosphonate structure. 
When the intermediate for (3S,4S)-4 was built and 
minimized, the best structure obtained presented several 
structural differences with regards to the (R,R)-enantiomer 
(Figure 3). Although all essential-hydrogen bonds existed 
too, due to the acetyl moiety in 3-position bound into the 
medium nucleophile subsite, the carbocycle did not fit in 
this pocket, and the Cbz was not placed as stable as in the 
case of (3R,4R)-4. On the one hand, many destabilizing 
interactions appeared between the acetyl group and 
Trp104, Ala281 (both with the carbonyl), Gly39 (with the 
methyl), Leu278 and more importantly, with the catalytic 
His224 (both with the oxygen of the alcohol); on the other 
hand, the benzyloxycarbonyl moiety was placed at the top 
of the tunnel making unfavourable clashes between the 
carbonyl group and the hydrophobic chain of Ile285, and 
the phenyl ring with the carbonyl-backbone of Glu188. 
Molecular modelling studies agree with the experimental 
results, explaining the excellent enantioselectivity showed 
by CAL-B toward trans-diacetate 4. Thus, although all 
essential hydrogen-bonds were present for both 
intermediates, better fitting of the (R,R)-enantiomer into 
the active site of the lipase, and more stabilizing 
interactions with the amino acids which are surrounding it 
can be the key explanation for this resolution. 
Furthermore, in the (S,S)-structure, the acetyl in 3-
position seemed to be very close from the catalytic 
His224, what might destabilise its position for the 
necessary transfer of the proton to the reactive carbonyl. 
Looking at these structures, a plausible explanation for the 
bad enantioselectivity in the acetylation of the diol 
derivative trans-(±)-6 could be established. Thus, the only 
difference between the first tetrahedral intermediate in the 
hydrolysis process, and the second tetrahedral 
intermediate in the acetylation reaction, is that in the first 
case at the 3-position there is an acetoxy group, and in the 
second one there is an hydroxyl moiety at this position. 
Some of the main structural differences obtained between 
both enantiomers were based on the altered interactions of 
the 3-O-acetyl group with the amino acids close to the 
lipase active-site. Thus, while for the (R,R) structure they 
were stabilizing (see green interactions in Figure 2), in the 
(S,S) enantiomer they destabilized the intermediate (see 
red interactions in Figure 3). Since this moiety is not 
present in the acetylation intermediates both structures 
would present less differences. 
3. Conclusions 
This paper describes an easy methodology for the 
preparation of both enantiomers of trans-1-
benzyloxycarbonyl-3,4-dihydroxypiperidine and the 
(R,R)-3-O-monoacetylated derivative via a lipase 
catalyzed hydrolysis. Thus, among all the lipases tested, 
CAL-B presented the best results, since allows obtaining 
one of the six possible products of this reaction (four 
monoalcohols and two diols) with high yield, showing 
this process total regio- and enantioselectivity at the same 
time. Attempts to acetylate the trans-diol (±)-6 afforded 
good regioselectivity but lower reaction rates and 
enantioselectivities. 
Molecular modelling has been used in order to rationalize 
these experimental facts. Thus, phosphonate analogues of 
both enantiomers of diacetate 4 were built and minimized, 
obtaining several structural divergences that can explain 
the excellent enantioselectivity obtained in the hydrolysis 
reaction with this substrate. 
On the other hand, from the results shown in this paper, it 
is apparent that the cis-isomer is not a suitable substrate 
for the tested lipases, neither through hydrolysis nor 
acylation processes. 
Taking into account the simplicity and easy scale-up of 
lipase catalyzed reactions,
28
 it is noteworthy the 
applicability of this method for the preparation of the 
gastroprokinetic agent cisapride and other optically pure 
structures with highly interesting biological properties. 
 
 Tetrahedron 6 
4. Experimental
 
General Remarks. Enzymatic reactions were carried out 
in a Gallenkamp incubatory orbital shaker. Immobilized 
Candida antarctica lipase B, CAL-B Novozym 435 (7300 
PLU/g), was a gift from Novo Nordisk co. Candida 
antarctica lipase B (CAL-B-L2, CHIRAZYME L-2, c-f, 
C3, 400 U/g), Candida rugosa lipase (CRL, 
CHIRAZYME L-3, >250 U/mg) and Candida antarctica 
lipase A (CAL-A, CHIRAZYME L-5, 1 kU/g) were 
supplied by Roche Molecular Biochemicals. 
Pseudomonas cepacia lipase lyophilized (PSL, 30000 
U/g) and immobilized (PSL-C, 783 U/g) are 
commercialized by Amano Pharmaceuticals. 
Chemical reagents were commercialized by Aldrich, 
Fluka, Lancaster or Prolabo. Solvents were distilled over 
an appropriate desiccant under nitrogen. Flash 
chromatography was performed using Merck silica gel 60 
(230-400 mesh). Optical rotations were measured using a 
Perkin-Elmer 241 polarimeter and are quoted in units of 
10
-1
 deg cm
2
 g
-1
.
1
H-NMR, 
13
C-NMR and DEPT spectra 
were recorded in a Bruker AC-300, Bruker AC-300 DPX 
and Bruker NAV-400 spectrometer using CDCl3 as 
solvent. The chemical shift values () are given in ppm. 
Positive electrospray ionisation (ESI
+
) was used to record 
mass spectra on an Hewlett-Packard 110 LC/MSD Series 
spectrometers. The enantiomeric excesses were 
determined by chiral HPLC analysis on a Hewlett-
Packard 1100, LC liquid chromatograph, using a 
CHIRALCEL OD for the diacetylated derivative 4. The 
diol 6 and the monoacetylated products 5 and 7 were first 
acetylated to convert them into the diacetate derivative 4 
and then analyzed. 
Molecular Modelling. The program Insight II, version 
2000.1, was used for viewing the structures. The 
geometric optimizations were performed using Discover, 
version 2.9.7 (Accelrys, San Diego CA, USA), using the 
AMBER force field.
27
 The distance dependent dielectric 
constant was set to 4.0 to mimic the electrostatic shielding 
of the solvent and the 1-4 van der Waals interactions were 
scaled to 50%. The crystal structure for the CAL-B 
(1LBS
16a
) was obtained from the Protein Data Bank 
(www.rcsb.org/pdb/). Protein structures in Figures 2 and 3 
were generated using PyMOL 0.97.
29
 The methodology 
followed for localization of energy minima structures by 
means of a systematically search has been described 
elsewhere.
16g
 
4.1. Synthesis of 1-Benzyloxycarbonyl-1,2,5,6-
tetrahydropyridine, (2). Benzyl chloroformate (3.8 mL, 
26.3 mmol) was added dropwise to a stirred mixture of 
1,2,5,6-tetrahydropyridine 1 (2.0 g, 21.9 mmol) and 
NaHCO3 (2.8 g, 26.3 mmol) in H2O (50 mL) at 0 ºC, and 
the mixture was stirred at room temperature for 4 h. After 
this time CH2Cl2 (50 mL) and 5% aqueous Na2CO3 (20 
mL) were added, the organic phase was separated, and the 
aqueous phase was extracted with CH2Cl2 (50 mL). The 
combined organic phases were dried over Na2SO4, the 
solvent was removed under reduced pressure and the 
crude residue was purified by flash chromatography on 
silica gel (hexane/ EtOAc 3:1) to afford the Cbz-protected 
product 2 as a yellow oil (4.4 g, 85%). 
1
H-NMR (CDCl3, 
300.13 MHz):  7.36 (m, 5 H), 5.81 (br s, 1 H), 5.64 (br s, 
1 H), 5.16 (s, 2 H), 3.96 (m, 2 H), 3.57 (m, 2 H), 2.14 (m, 
2 H); 
13
C-NMR (CDCl3, 75.5 MHz):  155.2 (CO), 136.6 
(C), 128.2 (CH), 127.7 (CH), 127.6 (CH), 125.1 (CH), 
124.8 (CH), 66.7 (CH2), 43.1 (CH2), 40.1 (CH2), 24.7 
(CH2); IR (CH2Cl2):  1713, 1630, 1425 cm
-1
; MS (ESI
+
, 
m/z): 218 (M + H)+, 100%, 240 (M + Na)+, 30]. 
4.2. Synthesis of (±)-1-Benzyloxycarbonyl-3,4-
epoxypiperidine, [(±)-3]. A solution of m-CPBA (4.3 g, 
25.0 mmol) in dry CH2Cl2 (30 mL) was added dropwise 
to a stirred solution of 2 (3.9 g, 18.0 mmol) in dry CH2Cl2 
(20 mL) at 0 ºC, and the mixture was stirred at room 
temperature for 4 h, then washed with 5% aqueous K2CO3 
solution (20 mL), followed by a saturated aqueous NaCl 
solution (20 mL). The organic phase was dried over 
Na2SO4, the solvent was removed under reduced pressure 
and the crude residue was purified by flash 
chromatography on silica gel (hexane/ EtOAc 1:1) to 
afford the product (±)-3 as a yellow oil (3.8 g, 90%). 
1
H-
NMR (CDCl3, 300.13 MHz):  7.36 (m, 5 H), 5.10 (s, 2 
H), 3.85-3.72 (m, 2 H), 3.44 (m, 2 H), 3.23 (m, 2 H), 2.01 
(m, 2 H); 
13
C-NMR (CDCl3, 75.5 MHz):  155.2 (CO), 
136.3 (C), 128.4 (CH), 128.0 (CH), 127.8 (2 CH), 67.4 
(CH2), 55.3 (2 CH), 47.5 (CH2), 41.3 (CH2), 21.1 (CH2); 
IR (CH2Cl2):  1715, 1428, 1212 cm
-1
; MS (ESI
+
, m/z): 
234 (M + H)+, 10%, 256 (M + Na)+, 100%. 
4.3. Preparation of (±)-trans-3,4-Diacetoxy-1-
benzyloxycarbonylpiperidine, [(±)-trans-4]. To a 
solution of (±)-3 (0.95 g, 4.1 mmol) in acetic acid (35 
mL), acetic anhydride was added (1.6 mL, 17 mmol). 
Boron trifluoride etherate (507 L, 4.1 mmol) was slowly 
added, and the mixture was stirred at room temperature 
for 4 h. An aqueous saturated solution of NaHCO3 (10 
mL) was added, and the mixture extracted with EtOAc 
(20 mL). The organic phase was washed with saturated 
aqueous Na2CO3 solution (20 mL) followed by saturated 
aqueous NaCl solution (20 mL), and then was dried over 
Na2SO4. The solvent was removed under reduced pressure 
and the crude residue was purified by flash 
chromatography on silica gel (hexane/ EtOAc 1:1) to 
afford the product (±)-trans-4 as a yellow oil (1.2 g, 
90%). 
1
H-NMR (CDCl3, 400.13 MHz, 40 ºC):  7.38 (m, 
5 H), 5.18 (d, 2 H), 4.98 (s, 1 H), 4.83 (m, 1 H), 3.84 (dd, 
1 H, 
3
JHH 3.45, 
3
JHH 13.80 Hz), 3.71-3.47 (m, 3 H), 2.11-
2.01 (m, 1 H), 2.10 (s, 3 H), 1.97 (s, 3 H), 1.70 (m, 1 H); 
13
C-NMR (CDCl3, 100.6 MHz, 40 ºC):  169.7 (CO), 
169.5 (CO), 155.1 (CO), 136.2 (C), 128.3 (CH), 127.8 
(CH), 127.6 (CH), 68.0 (2 CH), 67.1 (CH2), 44.1 (CH2), 
40.1 (CH2), 26.1 (CH2), 20.8 (CH3); IR (CH2Cl2):  1737, 
1712, 1425, 1210 cm
-1
; MS (ESI
+
, m/z): 358 (M + Na)+, 
100%. 
4.4. Enzymatic hydrolysis of (±)-trans-4. The reaction 
mixture containing (±)-trans-4 (50 mg, 0.15 mmol), the 
appropriate amount of H2O (see Table I) and the lipase 
(50 mg) in the corresponding organic solvent (50 mL) was 
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shaken at 30 
o
C and 250 rpm in an orbital shaker. The 
progress of the reaction was monitored by TLC (hexane/ 
EtOAc 1:1) until the achievement of the required 
conversion. Then, the enzyme was removed by filtration 
and washed with the corresponding organic solvent. The 
solvent was evaporated under reduced pressure and the 
crude residue was purified by flash chromatography on 
silica gel (hexane/ EtOAc 1:1) to afford the 
monoacetylated product (3R,4R)-5 and the remaining 
substrate (3S,4S)-4. 
(3S,4S)-3,4-Diacetoxy-1-benzyloxycarbonylpiperidine, 
[(3S,4S)-4]. Yellow oil []D
25
 = + 30.6 (c = 1, CHCl3), ee 
>99 %. 
(3R,4R)-3-Acetoxy-1-benzyloxycarbonyl-4-
hydroxypiperidine, [(3R,4R)-5]. Yellow oil []D
25
 = –
20.2 (c = 1, CHCl3), ee >99 %. 
1
H-NMR (CDCl3, 400.13 
MHz, 40 ºC):  7.38 (m, 5 H), 5.16 (2s, 2 H), 4.66 (m, 1 
H), 4.03 (dd, 1 H, 
3
JHH 3.32, 
3
JHH 13.32 Hz), 3.88-3.80 (m, 
3 H), 3.25 (m, 1 H), 2.22 (br s, 1 H, OH), 2.06 (s, 3 H), 
2.04-2.00 (m, 1 H), 1.61 (m, 1 H); 
13
C-NMR (CDCl3, 
100.6 MHz, 40 ºC):  170.6 (CO), 155.3 (CO), 136.6 (C), 
128.5 (CH), 128.0 (CH), 127.9 (CH), 72.5 (CH), 69.4 
(CH), 67.3 (CH2), 44.4 (CH2), 40.8 (CH2), 30.8 (CH2), 
20.9 (CH3); IR (CH2Cl2):  3621, 1728, 1715, 1430, 1213 
cm
-1
; MS (ESI
+
, m/z): 316 (M + Na)+, 100%. 
4.5. Preparation of (±)-trans-1-Benzyloxycarbonyl-3,4-
dihydroxypiperidine, [(±)-trans-6]. To a solution of (±)-
trans-4 (1.2 g, 3.7 mmol) in MeOH (35 mL), a solution of 
a catalytic amount of NaOMe in MeOH (1 mL) was 
added. The mixture was stirred for 2 h, and then the 
solvent was evaporated under reduced pressure and the 
product was purified by flash chromatography on silica 
gel (hexane/ EtOAc 1:1) to afford the product (±)-trans-6 
as a yellow oil (0.85 g, 94%); 
1
H-NMR (CDCl3, 400.13 
MHz, 40 ºC):  7.35 (m, 5 H), 5.13 (s, 2 H), 4.25 (dd, 1 H, 
3
JHH 3.23, 
3
JHH 13.10 Hz), 4.11-4.08 (m, 3 H), 3.55-3.47 
(m, 2 H), 1.98 (m, 1 H), 1.50 (m, 1 H); 
13
C-NMR (CDCl3, 
100.6 MHz, 40 ºC):  155.3 (CO), 136.5 (C), 128.5 (CH), 
128.1 (CH), 127.9 (CH), 71.8 (2 CH), 67.4 (CH2), 47.8 
(CH2), 42.1 (CH2), 31.4(CH2); IR (CH2Cl2):  3618, 3447, 
1710, 1425, 1204 cm
-1
; MS (ESI
+
, m/z): 252 (M + H)+, 
30%, 274 (M + Na)+, 100%. 
4.6. Enzymatic acetylation of (±)-trans-6. The reaction 
mixture containing (±)-trans-6 (50 mg, 0.15 mmol), vinyl 
acetate (see table II) and the lipase (50 mg) in the 
corresponding organic solvent (50 mL) was shaken at 30 
o
C and 250 rpm in an orbital shaker. The progress of the 
reaction was monitored by TLC using the solvent system 
hexane/ EtOAc 1:1 until the required conversion was 
achieved. Then, the enzyme was removed by filtration 
and washed with the corresponding organic solvent. The 
solvent was evaporated under reduced pressure and the 
crude residue was purified by flash chromatography on 
silica gel (hexane/ EtOAc 1:1) to afford the 
monoacetylated product (3R,4R)-7 and the remaining 
substrate (3S,4S)-6. 
(3S,4S)-1-Benzyloxycarbonyl-3,4-dihydroxypiperidine, 
[(3S,4S)-6]. Yellow oil []D
25 
= –3.7 (c = 1, CHCl3), ee 
>99 %. 
(3R,4R)-4-Acetoxy-1-benzyloxycarbonyl-3-
hydroxypiperidine, [(3R,4R)-7]. Yellow oil []D
25
 –12.2 
(c = 1, CHCl3), ee >99 %. 
1
H-NMR (CDCl3, 400.13 MHz, 
40 ºC):  7.38 (m, 5 H), 5.15 (2s, 2 H), 4.77 (m, 1 H), 
4.13 (dd, 1 H, 
3
JHH 3.16, 
3
JHH 13.52 Hz), 3.97-3.87 (m, 3 
H), 3.19-2.92 (m, 1 H), 2.52 (br s, 1H, OH), 2.13 (s, 3 H), 
2.12-2.05 (m, 1 H), 1.59 (m, 1 H); 
13
C-NMR (CDCl3, 
100.6 MHz, 40 ºC):  171.0 (CO), 155.4 (CO), 136.5 (C), 
128.5 (CH), 128.1 (CH), 127.9 (CH), 74.7 (CH), 68.8 
(CH), 67.4 (CH2), 47.7 (CH2), 41.4 (CH2), 28.2 (CH2), 
21.1 (CH3); IR (CH2Cl2):  3520, 1717, 1432, 1218 cm
-1
; 
MS (ESI
+
, m/z): 294.1 (M + H)+, 40%, 316.1 (M + 
Na)
+
, 100%. 
4.7. Preparation of (±)-cis-1-Benzyloxycarbonyl-3,4-
dihydroxypiperidine, [(±)-cis-8]. To a solution of 2 (1.0 
g, 4.6 mmol) in acetone/H2O (1:1, 8 mL), N-
methylmorpholine N-oxide (0.8 g, 6.8 mmol) was added, 
followed by a solution of OsO4 in tert-butanol (0.8 mL, 
2.5 % w/v), then the mixture was stirred for five days at 
room temperature. A saturated solution of Na2S2O5 (60 
mL) was added and the mixture was extracted with 
EtOAc (5  40 mL); the organic phase was dried over 
Na2SO4, the solvent was removed under reduced pressure 
and the crude residue was purified by flash 
chromatography on silica gel (hexane/ EtOAc 1:2) to 
afford the product (±)-cis-8 as a yellow oil (0.88 g, 76%); 
1
H-NMR (CDCl3, 400.13 MHz, 0 ºC):  7.35 (m, 5 H), 
5.12 (2s, 2 H), 3.84-3.30 (m, 6 H), 1.82 (m, 1 H), 1.65 (m, 
1 H); 
13
C-NMR (CDCl3, 100.6 MHz, 0 ºC):  155.8 (CO), 
136.4 (C), 128.4 (CH), 128.0 (CH), 127.7 (CH), 68.4 
(CH), 67.8 (CH), 67.2 (CH2), 46.1 (CH2), 40.1 (CH2), 
29.6 (CH2); IR (CH2Cl2):  3534, 3427, 1715, 1423, 1210 
cm
-1
; MS (ESI
+
, m/z): 252 (M + H)+, 100%. 
4.8. Synthesis of (±)-cis-3,4-Diacetoxy-1-
benzyloxycarbonylpiperidine, [(±)-cis-9]. To a solution 
at 0ºC of (±)-cis-8 (0.9 g, 3.6 mmol) in CH2Cl2 (8 mL), 
Et3N (2.0 mL, 14.3 mmol) and a catalytic amount of 
DMAP, acetic anhydride (1.4 mL, 14.3 mmol) was added 
dropwise. The resulting mixture was stirred at room 
temperature for 8 h. Then the solvent was removed under 
reduced pressure and the crude residue was purified by 
flash chromatography on silica gel (hexane/ EtOAc 2:1) 
to afford the product (±)-cis-9 as a yellow oil (1.1 g, 
90%); 
1
H-NMR (CDCl3, 400.13 MHz, 0 ºC):  7.38 (m, 5 
H), 5.22-5.03 (m, 4 H), 4.07-3.95 (m, 2 H), 3.89-3.84 (m, 
2 H), 2.08 (s, 3 H), 2.02-1.81 (m, 2 H), 1.95 (s, 3 H); 
13
C-
NMR (CDCl3, 100.6 MHz, 0 ºC):  170.5 (2 CO), 155.5 
(CO), 136.4 (C), 128.7 (CH), 128.3 (CH), 128.0 (CH), 
69.5 (2 CH), 67.5 (CH2), 44.8 (CH2), 41.2 (CH2), 26.5 
(CH2), 21.1 (CH3); IR (CH2Cl2):  1740, 1716, 1432, 
1207 cm
-1
; MS (ESI
+
, m/z): 358 (M + Na)+, 100%. 
4.9. Enzymatic hydrolysis and acetylation of (±)-cis-8 
and (±)-cis-9. These reactions were carried out using the 
same procedures as described as for the trans derivatives. 
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